Being able to test newly synthesized molecules is a pivotal part of early-stage drug discovery, with the data from assays driving decisions on the next molecules to be developed. The waveRAPID technology enables testing of full kinetic parameters for up to 400 compound fragments unattended in a 24-hour period.
In this video, Dr. Trevor Askwith from Domainex presents how they are using waveRAPID to accelerate the analogue expansion in order to support their fragment and virtual screening hit ID platforms.
► More about Domainex: www.domainex.co.uk/
-------------------------------------------------------
► More about waveRAPID: www.creoptix.com/products/wav...
► About Creoptix: www.creoptix.com/about-us
► Get in touch with us: www.creoptix.com/contact
► Follow us on Linkedin: / creoptix
► Follow us on Twitter: / creoptix
-------------------------------------------------------
Creoptix AG
Zugerstrasse 76
8820 Waedenswil
Switzerland
Creoptix Inc.
c/o CliftonLarsonAllen LLP
111 South Bedford Street, Ste. 108
MA-01803 Burlington
USA